A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Hodgkin Lymphoma Clinical Trial

Official title:

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03505996
• Other study ID #: CS1001-202
• Secondary ID: CTR20180423
• Status: Completed
• Phase: Phase 2
• Start date: May 22, 2018
• Est. completion date: November 1, 2021

Study information

• Verified date: October 2022
• Source: CStone Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, single-arm phase II study to evaluate the efficacy and safety of CS1001 monotherapy for relapsed/refractory classical Hodgkin Lymphoma (rr-cHL)

Description:

Eligible subjects with rr-cHL who failed at least two prior lines of therapies are planned to receive CS1001 1200 mg intravenous infusion every three weeks until progression of disease, intolerable toxicity, consent withdrawn or death.The primary endpoint of this trial is objective response rate (ORR), as assessed by independent radiological review committee (IRRC) based on Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: November 1, 2021
• Est. primary completion date: February 19, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects with histologically confirmed cHL at study site.

2. Relapsed or refractory cHL that failed at least two lines of systemic therapy.

3. ECOG PS of 0-2.

4. Subjects with at least one measurable lesion at baseline.

5. Subjects treated by prior anti-cancer therapy whose toxicity resolved to baseline or =< Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03

6. Subjects who agree to use highly effective contraception.

Exclusion Criteria:

1. Nodular lymphocyte predominant Hodgkin lymphoma or grey zone lymphoma.

2. Primary site in central nervous system (CNS) or CNS involvement.

3. Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS1001.

4. Subjects who had systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS1001.

5. Subject who had chemotherapy, immune therapy or biological therapy as systemic anti-cancer treatment within 28 days prior to the first dose of CS1001.

6. Receipt of traditional medicinal herbal preparations within 7 days prior to the first dose of CS1001.

7. Known history of human immunodefiency virus (HIV) infection and/or acquired immune deficiency syndrome.

8. Subjects with active Hepatitis B or C infection.

9. Subjects with active tuberculosis infection.

10. Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti CTLA-4 monoclonal antibody.

11. Female subjects who are pregnant or breast-feeding.

For more information regarding trial participation, please contact at cstonera@cstonepharma.com

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma
• Lymphoma

Intervention

Biological:
• CS1001
Monoclonal antibody

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CStone Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	The percentage of subjects whose best overall response is either complete response or partial response evaluated by IRRC according to Criteria for Response Assessment of Lymphoma: Lugano 2014 Classification	From first patient first visit to 6 month after last patient first visit